



**Minutes of the
Annual General Meeting of Shareholders of 2025**

of

Asian Phytochemicals Public Company Limited

Monday, April 21, 2025 at 14.00 hrs.

via Electronic Means (E-AGM) only



**Minutes of the Annual General Meeting of Shareholders of 2025
of
Asian Phytochemicals Public Company Limited**

Date, Time and Place

The Meeting was held on April 21, 2025, at 14.00 hrs. via electronic means (E-AGM) only through the Inventech Connect system, which the system has been certified by the Electronic Transactions Development Agency (EDTA) and in accordance with the standards set by the Emergency Decree on Electronic Meetings, B.E. 2563 (2020) and other relevant laws and regulations.

Attendees

Directors

- | | |
|--|--|
| 1. Mrs. Maleeratna Plumchitchom | Chairperson of the Board of Directors,
Chairperson of the Audit Committee and
Independent Director |
| 2. Assoc. Prof. Dr. Varakorn Samakoses | Director, Audit Committee, and
Independent Director |
| 3. Prof. Dr. Praipol Koomsup | Director, Audit Committee, and
Independent Director |
| 4. Prof. Dr. Pichaet Wiriyaichitra | Director, Chairman of Executive
Committee and Chief Executive Officer |
| 5. Dr. Montien Sirisoonthornlak | Director |
| 6. Assoc. Prof. Arunee Wiriyaichitra | Director, Executive Committee and
Company Secretary |

Absentee Director

- | | |
|----------------------------|----------------------------------|
| 1. Dr. Jingjai Hanchanlash | Director and Executive Committee |
|----------------------------|----------------------------------|

The total number of directors attending the meeting was 6 of 7, representing 85.71% of the total number of directors.

The Company has 2 sub-committees which are the Audit Committee and the Executive Committee.

Executive

- | | |
|--------------------------|--|
| 1. Mrs. Apinya Ulumpanon | Assistant to Chief Executive Officer for
Accounting and Finance |
|--------------------------|--|

Legal Consultant

- | | |
|-------------------------|--------------------------------------|
| 1. Mr. Krittin Pollagan | JTJB International Lawyers Co., Ltd. |
|-------------------------|--------------------------------------|

Auditor

- | | |
|-----------------------|----------------------|
| 1. Ms. Sunanta Kumsuk | AST Master Co., Ltd. |
|-----------------------|----------------------|

Secretary of the Meeting

- | | |
|--------------------------------------|--------------------------|
| 1. Assoc. Prof. Arunee Wiriyaichitra | Secretary of the Meeting |
|--------------------------------------|--------------------------|

Mr. Krittin Pollagan, a legal advisor of JTJB International Lawyers Co., Ltd. is an independent mediator, to facilitate the AGM to be legitimate and to follow the Articles of Association of the Company, including being a witness to verify the vote in this Meeting.

The Chairman then assigned Assoc. Prof. Arunee Wiriyachitra, the Company secretary, to explain the procedures for asking questions during the meeting, voting, vote counting, and to continue presiding over the meeting. The Company secretary explained to the shareholders that during this meeting, the Company would be collecting, using, and disclosing personal data, as well as still images, audio, and video recordings of all participants, for the purposes of meeting documentation and report preparation. Additionally, the secretary provided details about the meeting's regulations and guidelines as follows:

- For voting in the shareholders meeting, shareholders will have votes equal to the number of shares they hold and/or receive as a proxy, which is considered 1 share equal to 1 vote.
- One shareholder has the right to vote to approve, disapprove, or abstain from voting. Shareholders who are custodians can split their votes.
- For Agenda 5, regarding the appointment of directors to replace those who retire by rotation, an individual election method will be used to comply with the principles of good corporate governance.
- Prior to reaching a resolution for each agenda, shareholders and proxies are given an opportunity to make inquiries or comments relevant to the agenda via message. Please select the agenda you want to ask questions or express opinions about. Then press the "Question" button, type the message you want to ask and press the "Send Question" button. However, if there are a large number of questions sent into the system or if the question is not related to the agenda being considered, the Company reserves the right to consider and select questions as appropriate. The Company will collect your other questions and answer them in the shareholder meeting report.
- During the voting process, the shareholders will select the agenda which they wish to vote and then press the "Vote" button. The system will display three voting options: "Approve", "Disapprove", and "Abstain". To change your vote, press the "Cancel Vote" button and cast a new vote.

If a shareholder has not voted within the specified time, the Company will assume that the shareholder agrees with the respective agenda. In this regard, votes can be modified until the Company announces the closure of voting for each agenda. The Company provides a one-minute voting in each agenda.

In the case where the meeting attendee receives a proxy from many shareholders using the same email and telephone number to confirm your identity in the proxy, the system will combine the names of those granting proxies in the same user account. Except using different email addresses and phone numbers to verify your identity, the system will not include the names of the proxies. But it will be used as a separate user account. To access other accounts, press to select the menu "User Account" and press the "Change Account" button to access the accounts of other proxies by changing accounts, the system will not remove votes from the meeting base.

In the event that the shareholders leave the Meeting before voting on any agenda is closed, their votes will not be counted as a quorum for the said agenda, nor will be

counted for the remaining agendas. However, leaving the quorum for any agenda will not prevent the shareholders or proxies from returning to the Meeting and voting on subsequent agendas.

- In counting the votes for each agenda, the Company will deduct the votes cast against or in abstention of an agenda from the total number of votes, and the remaining number will be treated as the votes of approval.
- For this Meeting, each agenda except Agenda 2 and 6 shall be approved by a majority vote of the shareholders attending and casting vote.
 - Agenda 2, it is for acknowledgement and not required to vote
 - Agenda 6 shall be approved by two-thirds of the shareholders attending. For the directors who are shareholders of the Company and have a vested interest in remuneration of the Meeting allowance of the directors shall not be entitled to vote in this agenda.
- In the event that shareholders encounter problems accessing the meeting or the voting system, please study and follow the instructions provided in the meeting invitation letter or select the “Help” menu in the system. Shareholders can contact Inventech's Call Center staff from the phone number or LINE Official that appears on the screen.
- If a system failure occurs during the shareholder's meeting, the shareholders will receive an email notification containing a backup link to return to the meeting via the backup system.

Then the chairperson informed the meeting that in this meeting, the Company has set the list of shareholders entitled to attend the 2025 Annual General Meeting of Shareholders (Record Date) in accordance with the Securities and Exchange Act B.E. 2535 as March 13, 2025, which shows that the Company has a total of 3,353 shareholders.

There are currently shareholders registered to attend the meeting as follows: 11 shareholders registered to attend the meeting in person, represented 398,337,821 shares and 35 shareholders by proxy, represented 17,122,392 shares, the total of 46 attendees, representing the number of shares 415,460,213 shares from the total number of shares 600,000,000 subscribed shares, or 69.2433% of all subscribed shares which constituted a quorum pursuant to the Company's Articles of Association. The Chairperson then declared the Annual General Meeting of Shareholders of 2025 open and proposed that the Meeting considered matters as set forth in the agenda.

Agenda 1 **To consider and certify the Minutes of the Annual General Meeting of Shareholders of 2024**

The Chairperson proposed the Meeting to certify the minutes of the Annual General Meeting of Shareholders of 2024 held on April 22, 2024, in which the Company has also disseminated the aforementioned documents via its website (www.apco.co.th) since May 2, 2024, including the Company had sent a copy of the said minutes to all shareholders for their consideration and approval along with the invitation to the Meeting in the form of QR

Code and the Company has not received any requirements to amend the aforementioned minutes whatsoever.

The Chairperson then asked the Meeting whether there were any further inquiries.

When there were no further inquiries, the Chairperson respectively requested the Meeting to certify the minutes of the Annual General Meeting of Shareholders of 2024. The Meeting considered the same and resolved as follows:

Resolution: The minutes of the Annual General Meeting of Shareholders of 2024 held on April 22, 2024 was approved as proposed by majority vote of the shareholders attending the meeting and have the right to vote. The voting result of this agenda was as follows:

For this agenda, there were shareholders attending and casting vote, totaling 416,726,813 shares.

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,725,313	99.9996
(2) Disapprove	-	0.0000
(3) Abstain	1,500	0.0004
(4) Void Ballots	-	0.0000
Total	416,726,813	100.0000

Agenda 2 To acknowledge the Company's performance of the previous year

The Chairperson proposed the Meeting to consider the Board of Directors' Annual Report together with relevant details as stipulated by law which its detail is as appeared in the 2024 Annual Report that was sent to all shareholders together with the invitation to the Meeting in the form of QR Code and assigned Khun Apinya Ulumpanon, Assistant to CEO for Accounting and Finance to report the overall performance of the business operations of the year 2024 as follows:

Particulars (Unit : Baht)	Separate Financial Statements 2024	Separate Financial Statements 2023	Increase / (Decrease) (Percent)
Total Assets	631,575,702	701,127,559	(9.92)
Total Liabilities	75,717,321	91,857,540	(17.57)
Total Shareholders' Equity	555,858,381	609,270,019	(8.77)
Sales	206,328,882	287,658,720	(28.27)
Finance income	17,228,329	18,414,275	(6.44)

Other income	3,339,419	1,089,908	206.39
Profit from operating activities	50,589,987	113,761,650	(55.53)
Profit for the year	54,171,857	106,792,565	(49.27)
Earnings per Share	0.0900	0.1780	(49.44)

For the matter of anti-corruption, the Company has a written anti-corruption policy. Details are shown in Form 56-1 One Report, page 110, which is sent to shareholders in QR Code format. The Board of Directors arranges for an annual review of the policy, including supporting the provision of knowledge and review understanding of the policy for the Company's employees. To date, the Company has not found any complaints of fraud and corruption.

The Chairperson then asked the Meeting whether there were any further inquiries.

When there were no further inquiries, the Meeting then acknowledged the overall performance of the business operations of the previous year.

Agenda 3 **To consider and approve the Company's financial statements for the fiscal year ended December 31, 2024**

The Chairperson proposed to the Meeting to approve the financial statements of the Company for the fiscal year ended December 31, 2024 which has been audited and certified by the auditor and received approval from the Audit Committee and certified by the Board of Directors' meeting No.1/2025 held on February 27, 2025 and assigned Khun Apinya Ulumpanon, Assistant to CEO for Accounting and Finance to report with the following details:

(Unit: Baht)

Particulars (Unit : Baht)	Consolidated Financial Statements		Increase / (Decrease) %	Separate Financial Statements		Increase / (Decrease) %
	2024	2023		2024	2023	
Total Assets	636,017,163	704,724,471	9.75	631,575,702	701,127,559	9.92
Total Liabilities	76,299,389	92,335,409	17.37	75,717,321	91,857,540	17.57
Total Shareholders' Equity	559,717,774	612,389,062	8.60	555,858,381	609,270,019	8.77
Sales	210,830,384	292,761,706	27.99	206,328,882	287,658,720	28.27
Finance income	14,788,146	15,690,672	5.75	17,228,329	18,414,275	6.44
Profit from operating activities	53,109,364	116,890,793	54.56	50,589,987	113,761,650	55.53
Profit for the year	55,767,211	108,735,211	48.71	54,171,857	106,792,565	49.27
Profit attributable to: Equity holders of the parent	54,710,895	107,491,429	49.10	54,171,857	106,792,565	49.27
Earnings per Share	0.091	0.1792		0.09	0.1780	

Details are as appeared in the statements of financial statements of the Company for the fiscal year ended December 31, 2024 which was provided to the shareholders together with the invitation of meeting in the form of QR Code.

The Chairperson then asked the Meeting whether there were any further inquiries.

- Mr. Nakhonchai Ketyoi, a shareholder, asked:

In the annual report, under the inventory section as of December 31, 2024, it was found that there was an increase in finished goods of 6.28 million baht, which was a result of producing goods to prepare for export. He asked how the company had managed the goods awaiting delivery until today. How long will they still be able to be sold?

Prof. Dr. Pichaet Wiriyachitra, Chief Executive Officer, explained that the products have a shelf life of 3 years and are produced to prevent production from being delayed in case there is a high volume of orders.

When there were no further inquiries, The Chairperson respectively requested the Meeting to approve the financial statements of the Company for the fiscal year ended December 31, 2024. The Meeting considered the same and resolved as follows:

Resolution: The financial statements of the Company for the fiscal year ended December 31, 2024 that was audited and certified by the auditor and received approval from the Audit Committee and certified by the Board of Directors' meeting was approved as proposed by majority vote of the shareholders attending the meeting and have the right to vote.

The Chairperson informed the Meeting that the total number of shareholders in attendance either in person or by proxy is 49 persons, representing 416,802,813 shares or 69.47% of all subscribed shares.

For this agenda, there were shareholders attending and casting vote totaling 416,802,813 shares. The voting result of this agenda was as follows:

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,445,613	99.9143
(2) Disapprove	-	0.0000
(3) Abstain	357,200	0.0857
(4) Void Ballots	-	0.0000
Total	416,802,813	100.0000

Agenda 4 To consider and approve the dividend payment from operation result of 2024

The Chairperson informed the Meeting that the Company's performance for the period ending December 31, 2024, the Company has yielded net profits in the consolidated financial statements of Baht 54,710,895 (Fifty-four million seven hundred and ten thousand eight hundred and ninety-five baht only) and in the separate financial statements of Baht

54,171,857 (Fifty-four million one hundred and seventy-one thousand eight hundred and fifty-seven baht only).

The Company has dividend payment policy to pay shareholders in the rate not less than 40 percent of Net Profit after the deduction of corporate income tax and legal reserve. The Company has already allocated its annual net profit as the legal reserve of ten percent of the registered capital as required by law. Therefore, there is no need to allocate net profit for the year 2024 as an additional reserve for the Company.

The Board of Directors has considered paying dividend from the net profit and retained earnings for 101.90 percent of the net profit from the separate financial statements, it is higher than the Company's dividend payment policy in amount of Baht 55,200,000 (Fifty-five million two hundred thousand baht only) at the rate of Baht 0.092 per share.

The dividend will be paid to shareholders that are entitled to receive dividends, whose name appeared in the Shareholders Register Book (Record Date), on April 29, 2025 and the date of dividend payment shall be on May 13, 2025.

Compare with the dividend payment rate of the year 2024 operating results and the previous year as follows:

Particulars	Business Operation Result	
	2024 (Proposal) (Baht)	2023 (Previous Year) (Baht)
1. Net Profits (Baht) (Separate Financial Statements)	54,171,857	106,792,565
2. Dividend Payment Per Share (Baht/Share)	0.092	0.18
Number of Shares (Shares)	600,000,000	600,000,000
3. Rate of Dividend Payment Per Net Profit (Percentage)	101.90	101.06

The Chairperson then asked the Meeting whether there were any further inquiries.

When there were no further inquiries, the Chairperson respectively requested the Meeting to approve profits appropriation as legal reserve and dividend payment from business operation result of 2024. The Meeting considered the same and resolved as follows:

Resolution: the dividend payment from the business operation result of 2024 of the net profit and retained earnings at the rate of Baht 0.092 per share in total amount of Baht 55,200,000 (Fifty-five million two hundred thousand baht only).

Further, it is appropriate to pay dividends to entitled Shareholders whose names appeared in the Shareholders Register Book (Record Date) on April 29, 2025. The date of dividend payment shall be on May 13, 2025 was approved as proposed by majority vote of the shareholders attending the meeting and have the right to vote.

The Chairperson informed the Meeting that the total number of shareholders in attendance either in person or by proxy is 49 persons, representing 416,802,813 shares or 69.47% of all subscribed shares.

For this agenda, there were shareholders attending and casting vote, totaling 416,802,813 shares. The casting vote result of this agenda was as follows:

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,801,313	99.9996
(2) Disapprove	-	0.0000
(3) Abstain	1,500	0.0004
(4) Void Ballots	-	0.0000
Total	416,802,813	100.0000

Agenda 5 **To consider and approve the election of directors to replace those who retire by rotation**

The Chairperson informed the Meeting that the Company has a total of 7 directors. In the Annual General Meeting of Shareholders of 2025, there are two directors of the Company who have to retire by rotation which is one-third of all of the directors as follows:

- | | |
|-----------------------------------|----------|
| 1. Prof. Dr. Pichaet Wiriyachitra | Director |
| 2. Dr. Jingjai Hanchanlash | Director |

Prof. Dr. Pichaet Wiriyachitra left the meeting room for the transparency of the election process in this agenda,

The Chairperson further explained to the Meeting that in electing new directors to replace directors who retire by rotation, the directors who retire by rotation are eligible to be re-elected to resume their position. In compliance with the Good Corporate Governance Principles, the Company provides opportunities for the shareholders to propose directors nominees in advance of the Meeting, through an announcement on the Company's website and announcements from the SET since September 27, 2024 to December 31, 2024. For this Meeting, there are no directors nominees proposed by any shareholder.

The Board of Directors, excluding the directors who have a conflict of interest in this matter have screened individual directors carefully in accordance with the criteria of qualifications, knowledge, competence and experience in various fields including the performance in the previous position. Such a review revealed that all two Directors had carefully performed their duties; always concentrated on their duties, including providing advice and opinion to the Company and shareholders. They do not have any prohibited characteristics as prescribed by related laws and regulations, the Company's Articles of Association, the Corporate Governance and the composition of the Board of Directors. Therefore, it is appropriate to appoint him as a director of the Company for another term.

The Chairperson then asked the Meeting whether there were any further inquiries and when there were no further inquiries, the Chairperson respectively asked the Meeting to approve the election of directors to replace the directors who retire by rotation. The Meeting considered the same and resolved as follows:

Resolution: The appointments of Prof. Dr. Pichaet Wiriyachitra was approved as proposed by unanimous vote of the shareholders attending the meeting and have the right to vote, and the appointments of Dr. Jingjai Hanchanlash was approved as proposed by majority vote of the shareholders attending the meeting and have the right to vote.

The Chairperson informed the Meeting that the total number of shareholders in attendance either in person or by proxy is 49 persons, representing 416,802,813 shares or 69.47% of all subscribed shares.

The individually casting vote result of this agenda was as follows:

- 1) Prof. Dr. Pichaet Wiriyachitra
There were shareholders attending and casting vote, totaling 416,802,813 shares.

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,802,813	100.0000
(2) Disapprove	-	0.0000
(3) Abstain	-	0.0000
(4) Void Ballots	-	0.0000
Total	416,802,813	100.0000

- 2) Dr. Jingjai Hanchanlash
There were shareholders attending and casting vote, totaling 416,802,813 shares.

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,801,313	99.9996
(2) Disapprove	-	0.0000
(3) Abstain	1,500	0.0004
(4) Void Ballots	-	0.0000
Total	416,802,813	100.0000

Agenda 6 To consider and approve the Director's remuneration of 2025

The Chairperson informed the Meeting that the Board of Directors' meeting No.1/2025 held on February 27, 2025 has carefully considered the expansions of the business and growth of the Company's profits, and deemed it appropriate to specify the remuneration for the directors for year 2025 with details as follows:

- The remuneration of meeting allowance for the directors of year 2025 is the same rate of year 2024 as follows:

The Remuneration of Meeting Allowance	2025 (Proposal) (Baht per Person)	2024 (Previous Year) (Baht per Person)
<u>Meeting Allowance for Directors</u>	Rate per single attendance	Rate per single attendance
- Chairperson of the Board	25,000	25,000
- Director	20,000	20,000
<u>Meeting Allowance for Audit Committee</u>	Rate per single attendance	Rate per single attendance
- Chairperson of the Audit Committee	25,000	25,000
- Audit Committee	20,000	20,000
<u>Meeting allowance for Executive Committee</u>	Rate per single attendance	Rate per single attendance
- Executive Committee	15,000	15,000

However, those directors who received remuneration in the form of salaries are not paid.

- The remuneration for Directors in the form of bonus for the year 2025 is the same rate of year 2024 as follows:

	2025 (Proposed)	2024 (Previous Year)
Bonus rate (Percentage of sales revenue from the previous year)	0.175	0.175
Directors who will be allocated (Averaged by the number of the Directors)	Directors who do not receive compensation in the form of salary.	Directors who do not receive compensation in the form of salary.

- Other remuneration of directors

	2025 (Proposed)	2024 (Previous Year)
Other remuneration	-None-	-None-

The remuneration of meeting allowance for directors, sub-committees and Director's bonus for the year 2025, total amount not exceeding Baht 1.5 million (-One million five hundred thousand baht only-).

The Chairperson then asked the Meeting whether there were any further inquiries.

When there were no further inquiries, the Chairperson respectively requested the Meeting to approve the director's remuneration. The Meeting considered the same and resolved as follows:

Resolution: The remuneration for directors, sub-committees and Director's bonus for the year 2025 was approved as proposed by a vote of not less than two-thirds of the total number of votes of Shareholders attending the Meeting.

The Chairperson informed the Meeting that the total number of shareholders in attendance either in person or by proxy is 49 persons, representing 416,802,813 shares, or 69.47% of all subscribed shares.

For this agenda, there were shareholders attending the Meeting totaling 416,802,708 shares. The casting vote result of this agenda was as follows:

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,801,208	99.9996
(2) Disapprove	-	0.0000
(3) Abstain	1,500	0.0004
(4) Void Ballots	-	0.0000
Total	416,802,708	100.0000

Dr. Jingjai Hanchanlash and Dr. Montien Sirisoonthornlak as the interested party in the agenda of the directors' meeting remuneration is not entitled to vote in this agenda.

Agenda 7 To consider and approve the appointment of auditors and determine the remuneration for the year 2025

The Chairperson explained that in accordance with the Public Company Limited Act B.E. 2535 and the Article of Association of the Company, it is stipulated that the Annual General Shareholders Meeting shall annually appoint the auditors which the Office of the Securities and Exchange Commission approves of and fix their remuneration. Therefore, the Audit Committee, therefore, proposes the appointment of the auditors for the year 2025 as the auditors of Asian Phytoceuticals Public Company Limited from the list below:

<u>Name of Auditor</u>	<u>CPA Registration No.</u>	<u>Year of auditing</u>
1. Miss Nongram Laohaareedilok	4334	2014 – 2016, 2019 - 2020 and/or
2. Miss Chamaporn Rodloytook	9211	- and/or
3. Miss Pakamon Laohaarreedilok	11499	-

from AST Master Co., Ltd. who are approved auditors by the SEC to be the auditors of the Company of 2025. AST Master Co., Ltd. is a reliable Company and the auditors of this Company have been performing auditing functions with a good performance

and have no relationship or conflict of interests with the Company, affiliates, management, major shareholders including their related persons, which would affect the independence of their performing. The Company will arrange for the auditor rotation. If any person acting as an auditor is in charge of auditing or reviewing the financial statements of the Company for 7 fiscal years, regardless of whether they are consecutively or not according to the notification of the Capital Market Supervisory Board.

For the auditors' remuneration of 2025, the quotation for audit service for the Company including the proposed quarterly reviewed of audit fee Baht 1,300,000 (One million, three hundred thousand baht only), the same rate as year 2024. The comparison of auditors' remuneration of the proposal year and 2024 is as follow:

Particulars	Amount (Baht)	
	2025 (Proposed)	2024 (Previous Year)
1. Audit fee and Quarterly reviewed fee		
- Audit fee	930,000	930,000
- Quarterly review of financial statements	330,000	330,000
- Fee for reviewing consolidated financial statements	40,000	40,000
2. Non-Audit Fee	-	-
Grand Total	1,300,000	1,300,000

The Chairperson further informed the Meeting that three auditors, Miss Nongram Laohaareedilok, Miss Chamaporn Rodloytook, and Miss Pakamon Laohaareedilok do not have relationships or stakes in the Company, the subsidiary, the executives, the major shareholders or the connected person of such persons whatsoever and then asked the Meeting whether there were any further inquiries.

When there were no further inquiries, the Chairperson respectively requested the Meeting to consider and approve the appointment of the Company's auditors and determination of the auditors' remuneration of 2025. The Meeting considered the same and resolved as follows:

Resolution: The appointment of Miss Nongram Laohaareedilok, Certified Public Accountant No. 4334 and /or Miss Chamaporn Rodloytook, Certified Public Accountant No. 9211 and/or Miss Pakamon Laohaareedilok Accountant No.11499 from AST Master Co., Ltd., who are auditors which the Office of the Securities and Exchange Commission approves, as auditors of the Company for the year 2025 and the fixing of the remuneration for the auditors for the year 2025 in the amount of 1,300,000 Baht (One million, three hundred thousand baht only) was approved as proposed by majority vote of the shareholders attending the meeting and have the right to vote.

The Chairperson informed the Meeting that the total number of shareholders in attendance either in person or by proxy is 49 persons, representing 416,802,813 shares, or 69.47% of all subscribed shares.

The voting result of this agenda was as follows:

For this agenda, there were shareholders attending and casting vote, totaling 416,802,813 shares.

Shareholders	Amount (Votes)	Percentage
(1) Approve	416,801,313	99.9996
(2) Disapprove	-	0.0000
(3) Abstain	1,500	0.0004
(4) Void Ballots	-	0.0000
Total	416,802,813	100.0000

The Chairperson then asked the Meeting whether there were any further inquiries.

- Mr. Sitthisak Puyog, a shareholder, asked:

Has the decline in revenue been caused by distribution channels, such as online sales, not being widespread enough? Currently, there is no official online sales channel.

Prof. Dr. Pichaet Wiriyachitra, Chief Executive Officer, explained that the decrease in income was due to the economic situation that occurred in every company nationwide. APCO is still better than others that do not suffer losses.

- Mr. Nakhonchai Ketyoi, a shareholder, asked:

1) What are the top 3 champion products with the highest sales of APCO? How much is the sales of each product? What percentage of total sales is it?

Prof. Dr. Pichaet Wiriyachitra, Chief Executive Officer, explained that the number 1 product is a product for cancer patients, number 2 is a product for Watanachiwa, and number 3 is a product for HIV patients.

2) How are the sales of products via Tik Tok for Cancino, MylifeT, and Super Hi-Sol products? How many baht can be generated in sales per month?

Prof. Dr. Pichaet Wiriyachitra, Chief Executive Officer, explained that the TikTok sales channel is still in its early stages.

3) How are the sales going for products sold to Chinese tourists coming to participate in gaming events in Thailand? The company has indicated about 2,000 people per month purchasing products like Cancino, Mylife100Plus, MMM, and Mangosteen juice. How is this progressing, and what is the accumulated revenue?

Prof. Dr. Pichaet Wiriyachitra, Chief Executive Officer, explained that this project was initiated last year, and there were delays in obtaining the necessary approvals. However, the project has now been approved, and we expect the first group of tourists, approximately 500-2,000 people, to start arriving around July 30, 2025.

4) Please provide an update on the "Quickest ByeBye HIV" competition, which had 13 participants and was scheduled to end on April 20, 2025. What is the current status of the competition?

Prof. Dr. Pichaet Wiriyaichitra, Chief Executive Officer, explained that as this is a project where products were provided for free, we found that the participants did not use the products consistently, so the project has been paused. However, in terms of product efficacy, two international journal articles have been published this month, showcasing that users of the product are now HIV-negative and can stop using the product for up to 10 years.

5) In 2024, the company had advertising and promotional expenses of 33.12 million baht. It has been observed that, over the past two years, the company has primarily invested in online media and the TV show "Baai Nee Mee Kham Tohp". Does the company consider this investment worthwhile, and are there plans to expand into other media channels, such as well-known TV shows?

Prof. Dr. Pichaet Wiriyaichitra, Chief Executive Officer, explained that the program "'Baai Nee Mee Kham Tohp'" is a program where the company can describe the characteristics of the company's products, which is different from other channels. Although the income from this channel is not much, it is a channel where product users continuously use the products, which is a long-term investment and generates income effectively. As for YouTube and Facebook, they are not very well received, but the company must continue because there are also continuous users. What the company is trying to do now is to increase the quality of the products and raise the level of its standard to be number 1 then wait for the market to recover. As for the Nigerian market, the products have been registered in Nigeria, but until now, there has been no approval, so it has opened up opportunities for other companies to enter. Currently we are in negotiations to produce and sell 11 products throughout Africa, with the contract expected to be signed in June.

• Mr. Preecha Sapkitjakan, a shareholder, asked:

1) What is the progress regarding Chinese tourists purchasing products from the company, with an estimated 2,000 people per month buying at 6,500 baht each starting in April?

2) What is the progress regarding the first signed HIV product distributor in Nigeria, who was supposed to visit the company in early April?

3) What is the progress with the new potential distributors for HIV products in Nigeria, including 11 items?

4) What are the company's marketing plans in Thailand to boost sales, such as the "Buy 5, Get 1 Free" program?

Prof. Dr. Pichaet Wiriyaichitra, Chief Executive Officer, explained that questions 1-3 were answered earlier. Regarding the domestic marketing plan, the "Buy 5, Get 1 Free" program is no longer deemed appropriate. The Company has shifted its focus to using the BIM Supervisor and BIM Advisor channels. The supervisor and advisor will be the ones to recommend products. When the symptom of the user gets better, consumers will recommend to others.

• Mr. Sitthisak Puyog, a shareholder, asked how many meetings are held per year and what are the conditions for holding the meeting?

Mrs. Apinya Ulumpanon, Assistant to Chief Executive Officer for Accounting and Finance, explained that the company holds 5 board meetings per year and 4 audit committee meetings per year.

When there were no further inquiries, the Chairperson on behalf of the Board of Directors thanked all shareholders and declared the Meeting adjourned at 15.15 hrs.

-Signature-

(Ms. Maleeratna Plumchitchom)
Director and Chairperson of the Meeting

-Signature-

(Assoc. Prof. Arunee Wiriyaichitra)
Director, Company Secretary,
and Secretary of the Meeting